{
  "ptid_time": "126_S_2407_2013-11-26",
  "img_path": "/data/qiuhui/data/adni/images/126_S_2407/2013-11-26/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 21,809 mm³, 22.3% below the reference mean. With a Z-score of -0.51 (30.5th percentile), this represents normal volume ; hippocampal volume measures 2,961 mm³, 58.4% below the reference mean. With a Z-score of -5.35 (0.0th percentile), this represents profound atrophy; whole brain volume measures 875,389 mm³, 10.2% below the reference mean. With a Z-score of -1.28 (10.0th percentile), this represents mild atrophy; entorhinal cortex volume measures 2,356 mm³, 35.9% below the reference mean. With a Z-score of -2.20 (1.4th percentile), this represents significant atrophy; fusiform gyrus volume measures 14,965 mm³, 12.0% below the reference mean. With a Z-score of -1.10 (13.7th percentile), this represents mild atrophy; middle temporal gyrus volume measures 17,198 mm³, 10.3% below the reference mean. With a Z-score of -0.89 (18.6th percentile), this represents normal volume . ",
  "text_data": "Age is 70.0 years. Gender is Female. Education: 16 years. MMSE: 29.0. MoCA: 25.0. Logical Memory: 8.0. APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 0.97 SUVR (normal ); Total tau: 257.50 pg/mL (normal ); Phosphorylated tau: 18.78 pg/mL (normal ). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The hippocampal volume shows profound atrophy (Z-score -5.35, 0.0th percentile), and the entorhinal cortex has significant atrophy (Z-score -2.20, 1.4th percentile), both strongly associated with Alzheimer's pathology. However, cognitive scores (MMSE 29, MoCA 25) are near-normal, suggesting preserved function despite structural decline. Biomarkers (T-tau, P-tau, AV45) are normal, reducing likelihood of active amyloid pathology.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)**  \n**Confidence:** **Medium** (Structural atrophy is severe in key regions, but cognitive scores and biomarkers don't fully align with dementia. APOE4-negative status and normal biomarkers suggest slower progression.)  \n\n**Note:** Follow-up clinical correlation is critical—discrepancy between imaging and cognition may indicate *resilience* or *compensatory mechanisms*. Repeat neuropsychological testing in 6–12 months to track decline.",
  "timestamp": "2025-07-26T12:45:05.212854"
}